Prompt effects of high-level irradiation on animal metabolism.

J. Ellis,R. Clark,W. Rambach,J. Pickering

Abstract:

What problem does this paper attempt to address?

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

Yongjing Chen,Zhenhua Hu,Qin Wang,Yan Ge,Lixiong Bai,Xuefeng Wang,Xueguang Zhang

DOI: https://doi.org/10.1089/hyb.2009.0091

2010-01-01

Hybridoma

Abstract:Programmed death-1 (PD-1, CD279), an inhibitory co-stimulatory molecule of the CD28 superfamily, plays a critical role in immune response. In this report, four novel mouse anti-human PD-1 monoclonal antibodies (MAbs) were prepared using hybridoma technology and immunological characteristics of the MAbs were determined. The results showed that all the MAbs (clones 9H1, 4B9, 8F5, and 1F8) were IgG1(kappa) and bound specifically to human PD-1. By mutual competition, we found that the antibodies recognized three different epitopes of PD-1 antigen and 9H1 MAb could block both PD-1/PD-L1 and PD-1/PD-L2 interaction. Cross-linking of PD-1 with MAb 9H1 markedly blocked PD-1 negative signal and promoted T cell proliferation. In addition, 4B9 and 9H1 MAbs were suitable for indirect ELISA detection. Thus, the MAbs against human PD-1 with high specificity and different activity would be useful for the further study of this molecule.
O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

Qiang Zhu,Hongxing Wang,Siyuan Chai,Liang Xu,Bingyi Lin,Wen Yi,Liming Wu

DOI: https://doi.org/10.1073/pnas.2216796120

2023-01-01

Abstract:Programmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 (PD-1) mediate T cell-dependent immunity against tumors. The abundance of cell surface PD-L1 is a key determinant of the efficacy of immune checkpoint blockade therapy targeting PD-L1. However, the regulation of cell surface PD-L1 is still poorly understood. Here, we show that lysosomal degradation of PD-L1 is regu-lated by O-linked N-acetylglucosamine (O-GlcNAc) during the intracellular traffick-ing pathway. O-GlcNAc modifies the hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), a key component of the endosomal sorting machinery, and subsequently inhibits its interaction with intracellular PD-L1, leading to impaired lysosomal degradation of PD-L1. O-GlcNAc inhibition activates T cell-mediated antitumor immunity in vitro and in immune-competent mice in a manner dependent on HGS glycosylation. Combination of O-GlcNAc inhibition with PD-L1 antibody synergistically promotes antitumor immune response. We also designed a competitive peptide inhibitor of HGS glycosylation that decreases PD-L1 expression and enhances T cell-mediated immunity against tumor cells. Collectively, our study reveals a link between O-GlcNAc and tumor immune evasion, and suggests strategies for improving PD-L1-mediated immune checkpoint blockade therapy.
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.

R. Dadu,C. Devine,Mike Hernandez,S. Waguespack,N. Busaidy,Mimi I Hu,C. Jimenez,M. Habra,R. Sellin,A. Ying,G. Cote,S. Sherman,M. Cabanillas

DOI: https://doi.org/10.1210/jc.2013-3588

2014-03-14

Abstract:CONTEXT Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. OBJECTIVE The objective of the study was to determine the efficacy of salvage therapy after first-line sorafenib failure. DESIGN This was a retrospective review at M. D. Anderson Cancer Center from January 2005 to May 2013. PATIENTS The study included patients with metastatic DTC who received salvage therapy after their initial sorafenib failure (group 2). PATIENTS who received first-line sorafenib only (group 1) were evaluated for comparison of overall survival (OS). OUTCOME MEASURES Progression-free survival, best response, and median OS were measured. RESULTS Sixty-four patients with metastatic, radioactive iodine refractory DTC were included; 35 were in group 1 and 25 were in group 2, and the groups were well balanced. Median OS of all 64 patients receiving first line sorafenib was 37 months; median OS was significantly longer with salvage therapy compared with sorafenib alone (58 vs 28 months, P = .013). In group 2, 17 patients were evaluable for best response, although two patients had toxicity with sorafenib, which was discontinued before restaging. Best responses with first-line sorafenib were partial response in 2 of 15 (13%), stable disease in 10 of 15 (67%), and progressive disease in 3 of 15 (20%) patients. With salvage therapy, partial responses were seen in 7 of 17 (41%) and stable disease in 10 of 17 (59%) patients. Median progression-free survival was 7.4 months with first-line sorafenib and 11.4 months with salvage therapy. Salvage therapy included sunitinib (n = 4), pazopanib (n = 3), cabozantinib (n = 4), lenvatinib (n = 3), and vemurafenib (n = 3). CONCLUSIONS Other targeted agents are effective salvage treatments after sorafenib failure, despite similar mechanisms of action, and should be offered to patients who are able to receive salvage therapy.
N-glycosylation of PD-1 promotes binding of camrelizumab

Kefang Liu,Shuguang Tan,Wanjun Jin,Jiawei Guan,Qingling Wang,Huan Sun,Jianxun Qi,Jinghua Yan,Yan Chai,Zhongfu Wang,Chuxia Deng,George F. Gao

DOI: https://doi.org/10.15252/embr.202051444

IF: 9.071

2020-01-01

EMBO Reports

Abstract:PD-1 is a highly glycosylated inhibitory receptor expressed mainly on T cells. Targeting ofPD-1 with monoclonal antibodies (MAbs) to block the interaction with its ligandPD-L1 has been successful for the treatment of multiple tumors. However, polymorphisms at N-glycosylation sites ofPD-1 exist in the human population that might affect antibody binding, and dysregulated glycosylation has been observed in the tumor microenvironment. Here, we demonstrate varied N-glycan composition inPD-1, and show that the binding affinity of camrelizumab, a recently approvedPD-1-specificMAb, to non-glycosylatedPD-1 proteins fromE. coliis substantially decreased compared with glycosylatedPD-1. The structure of the camrelizumab/PD-1 complex reveals that camrelizumab mainly utilizes its heavy chain to bind toPD-1, while the light chain sterically inhibits the binding ofPD-L1 toPD-1. Glycosylation of asparagine 58 (N58) promotes the interaction with camrelizumab, while the efficiency of camrelizumab to inhibit the binding ofPD-L1 is substantially reduced for glycosylation-deficientPD-1. These results increase our understanding of how glycosylation affects the activity ofPD-1-specificMAbs during immune checkpoint therapy.
Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1

Z-F Li,C Chen,J-Y Zeng,S Wang,S-Q Han,Y-Q Zhang,D-D Qiu,H-X Guo

DOI: https://doi.org/10.26355/eurrev_202106_26040

Abstract:Objective: Programmed death ligand-1 (PD-L1) is expressed on tumor cells and macrophages. The detection of PD-L1 expression in cancer and the treatment by targeting the PD-L1/programmed death-1 (PD-1) are of great clinical significance. This work aims to screen the aptamers with high affinity and specificity for recombinant human PD-1 (rhPD-1)/recombinant human PD-L1 extracellular domain (rhPD-L1). Materials and methods: In this study, we have expressed, purified, prepared, and identified rhPD-1 and rhPD-L1. The rhPD-L1/rhPD-1 aptamers with high afﬁnity and speciﬁcity were obtained by systematic evolution of ligands by exponential enrichment technique. Ten aptamers sequences to rhPD-L1 and 10 aptamers sequences to rhPD-1 were obtained by cloning and sequencing. The afﬁnity and speciﬁcity of candidate aptamers were analyzed by gold nanoparticles-based colorimetric assay, dot blot assay, and electrophoretic mobility shift assay. Results: The aptamers named A6 were picked out as the optimal aptamers that recognize PD-1, speciﬁcally with the Kd value of 47.84 ± 24.78 nM. The aptamers named B10 were picked out as the optimal aptamers that recognize PD-L1, speciﬁcally with the Kd value of 59.72 ± 15.87 nM. Conclusions: The study lays a foundation for the development of detection methods and therapeutic drugs targeting PD-L1/PD-1.
Prognostic Value of Programmed Cell Death Protein 1 Expression on CD8+ T Lymphocytes in Pancreatic Cancer

Tao Shen,Liangjing Zhou,Hua Shen,Chengfei Shi,Shengnan Jia,Guo Ping Ding,Liping Cao

DOI: https://doi.org/10.1038/s41598-017-08479-9

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Pancreatic cancer is one of the most aggressive malignancies and has a highly immunosuppressive tumour microenvironment. Immune checkpoint blockade has led to remarkable and durable objective responses in a number of malignancies and antibody-based strategies targeting programmed cell death protein 1 (PD-1) are showing promise where traditional modalities of surgery, radiotherapy, and chemotherapy have failed. In this study, we examined the clinical value of PD-1 protein expression by CD8+ peripheral T lymphocytes or tumour-infiltrating T lymphocytes (TILs) in pancreatic ductal adenocarcinoma (PDAC). Expression of PD-1 protein on CD8+ TILs correlated with overall survival and clinicopathological characteristics such as clinical stage, N classification, and M classification. Similar findings were observed for the expression of PD-1 protein on peripheral CD8+ T cells, whereas its expression on peripheral CD4+ T cells showed no significance. Comparison of the levels of PD-1 protein expressed by peripheral CD8+ T cells before and 4 weeks after surgery indicated that preoperative and postoperative status of peripheral PD-1 expression was unchanged. Our findings showed that PD-1 protein expressed by peripheral or tumour-infiltrated CD8+ T cells was a promising biomarker for diagnosis and prognosis in PDAC and might help guide future immunotherapies.
Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker

Lin Zhu,Yuanfeng Xu,Siyin Kang,Bingqian Lin,Chi Zhang,Zhenlong You,Haoting Lin,Chaoyong Yang,Yanling Song

DOI: https://doi.org/10.1002/smtd.202200549

IF: 12.4

Small Methods

Abstract:Exosomal programmed cell death ligand 1 (exoPD-L1) has emerged as a promising biomarker for cancer diagnosis and immunotherapy outcome prediction. However, the existing quantitation methods are incapable of addressing the heterogeneity of exoPD-L1 glycosylation, which has been demonstrated to be the institutional basis for PD-L1/PD-1 interaction and the crucial participant in inhibiting the activity of CD8+ T cells. Herein, an aptamer- and lectin-induced proximity ligation assay combined with quantitative real-time polymerase chain reaction for precise quantitation of glycosylated exoPD-L1 is developed. Leveraging the metabolism-free lectin labeling of glycosylation, the glycosylation-independent aptamer tagging of PD-L1, and excellent selectivity of dual-recognition, this method enables glycosylated exoPD-L1 quantitation with high sensitivity and selectivity in a wash-free manner. As a result, this method is able to distinguish the levels of glycosylated exoPD-L1 between healthy donors and cancer patients with sensitivity and specificity of 100%. Compared with the total circulating exoPD-L1 level, glycosylated exoPD-L1 is for the first time identified to be a more reliable biomarker for tumor diagnosis. Overall, this strategy holds a great potential for revealing the significance of exoPD-L1 glycosylation and converting glycosylated exoPD-L1 into a reliable clinical indicator.
Silencing the androgen receptor: new skills for antiandrogen oligonucleotide skin and hair therapy.

A. Dugour,Karina Hagelin,Cintia Smus,M. Balañá,N. Kerner

DOI: https://doi.org/10.1016/j.jdermsci.2008.12.008

2009-05-01

Abstract:
Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells

Li Zhou,Fangni Chai,Yong He,Zhihui Zhou,Shupan Guo,Pan Li,Qi Sun,Xueyin Zu,Xin Liu,Qin Huang,Yanping Zhong,Aolan Zhou,Xueyun Wang,Haiyan Ren

DOI: https://doi.org/10.1038/s42003-022-03845-4

IF: 6.548

2022-08-30

Communications Biology

Abstract:Abstract Whether membrane-anchored PD-L1 homodimerizes in living cells is controversial. The biological significance of the homodimer waits to be expeditiously explored. However, characterization of the membrane-anchored full-length PD-L1 homodimer is challenging, and unconventional approaches are needed. By using genetically incorporated crosslinkers, we showed that full length PD-L1 forms homodimers and tetramers in living cells. Importantly, the homodimerized intracellular domains of PD-L1 play critical roles in its complex glycosylation. Further analysis identified three key arginine residues in the intracellular domain of PD-L1 as the regulating unit. In the PD-L1/PD-L1-3RE homodimer, mutations result in a decrease in the membrane abundance and an increase in the Golgi of wild-type PD-L1. Notably, PD-1 binding to abnormally glycosylated PD-L1 on cancer cells was attenuated, and subsequent T-cell induced toxicity increased. Collectively, our study demonstrated that PD-L1 indeed forms homodimers in cells, and the homodimers play important roles in PD-L1 complex glycosylation and T-cell mediated toxicity.

biology
Identification and Functional Characterization of Glycosylation of Recombinant Human Platelet- Derived Growth Factor-Bb in Pichia Pastoris

Mengmeng Dai,Changming Yu,Ting Fang,Ling Fu,Jing Wang,Jun Zhang,Jun Ren,Junjie Xu,Xiaopeng Zhang,Wei Chen

DOI: https://doi.org/10.1371/journal.pone.0145419

IF: 3.7

2015-01-01

PLoS ONE

Abstract:Yeast Pichia pastoris is a widely used system for heterologous protein expression. However, post-translational modifications, especially glycosylation, usually impede pharmaceutical application of recombinant proteins because of unexpected alterations in protein structure and function. The aim of this study was to identify glycosylation sites on recombinant human platelet-derived growth factor-BB (rhPDGF-BB) secreted by P. pastoris, and investigate possible effects of O-linked glycans on PDGF-BB functional activity. PDGF-BB secreted by P. pastoris is very heterogeneous and contains multiple isoforms. We demonstrated that PDGF-BB was O-glycosylated during the secretion process and detected putative O-glycosylation sites using glycosylation staining and immunoblotting. By site-directed mutagenesis and high-resolution LC/MS analysis, we, for the first time, identified two threonine residues at the C-terminus as the major O-glycosylation sites on rhPDGF-BB produced in P. pastoris. Although O-glycosylation resulted in heterogeneous protein expression, the removal of glycosylation sites did not affect rhPDGF-BB mitogenic activity. In addition, the unglycosylated PDGF-BBΔGly mutant exhibited the immunogenicity comparable to that of the wild-type form. Furthermore, antiserum against PDGF-BBΔGly also recognized glycosylated PDGF-BB, indicating that protein immunogenicity was unaltered by glycosylation. These findings elucidate the effect of glycosylation on PDGF-BB structure and biological activity, and can potentially contribute to the design and production of homogeneously expressed unglycosylated or human-type glycosylated PDGF-BB in P. pastoris for pharmaceutical applications.
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Xinfang Yu,Wei Li,Ken H. Young,Yong Li

DOI: https://doi.org/10.3390/biomedicines9111702

IF: 4.757

2021-11-16

Biomedicines

Abstract:Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory cytokines. PD-L1 expression levels on cancer cells might affect the clinical response to anti-PD-1/PD-L1 therapies. Hence, understanding molecular mechanisms for regulating PD-L1 expression is essential for improving the clinical response rate and efficacy of PD-1/PD-L1 blockade. Posttranslational modifications (PTMs), including phosphorylation, glycosylation, ubiquitination, and acetylation, regulate PD-L1 stability, cellular translocation, and interaction with its receptor. A coordinated positive and negative regulation via PTMs is required to ensure the balance and function of the PD-L1 protein. In this review, we primarily focus on the roles of PTMs in PD-L1 expression, trafficking, and antitumor immune response. We also discuss the implication of PTMs in anti-PD-1/PD-L1 therapies.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Palmitoylation is critically required for cancer intrinsic PD-1 expression and functions

Han Yao,Chushu Li,Jean-Philippe Brosseau,Huanbin Wang,Haojie Lu,Caiyun Fang,Hubing Shi,Jiang Lan,Jie Xu

DOI: https://doi.org/10.1101/625483

2019-05-02

Abstract:Abstract Programmed cell death protein 1 (PD-1) is a crucial anticancer target, but the relatively low response rate and acquired resistance to existing antibody drugs highlight an urgent need to develop alternative targeting strategies. Here we report the palmitoylation of PD-1, discovered the main DHHC enzyme for this modification, revealed the mechanism for its effect on PD-1 expression, and rationally developed a peptide for targeting PD-1 expression. Palmitoylation promoted the trafficking of PD-1 to recycling endosome, thus preventing its lysosome-dependent degradation. Palmitoylation was required for the activation of PD-1 downstream signaling, and targeting palmitoylation by pharmacological inhibitor or depleting the modification enzyme caused significant anti-tumor effects. A peptide was designed to competitively inhibit PD-1 palmitoylation and expression, opening a new route for developing PD-1 inhibitors as a strategy for cancer immunotherapy. Significance We show for the first time that PD-1 is palmitoylated, identify DHHC9 as the predominant enzyme for its palmitoylation, and reveal the molecular mechanisms underlying its effects on PD-1 stability and functions. Importantly, we also designed a competitive inhibitor targeting PD-1 palmitoylation, and this first-in-class molecule may inspire the development of new checkpoint inhibitors.
[Preparation and Identification of Monoclonal Antibodies Against Human Programmed Cell Death 10 (PDCD10)].

Yao-yao Chen,Yun-gang Zhao,Ting Zhang,Lan-jun Xu,Xi Ma,Hong-shan Zhao,Ying-yu Chen

DOI: https://doi.org/10.3321/j.issn:1671-167x.2006.06.006

2006-01-01

Abstract:OBJECTIVE:To obtain monoclonal antibodies against programmed cell death 10 (PDCD10) for further study of the structure and function of PDCD10 protein.METHODS:Balb/c mice were immunized with recombinant PDCD10, hybridoma cell lines secreting monoclonal antibodies against PDCD10 were screened by regular cell fusion and subcloning approach. The specificities of these monoclonal antibodies were determined by ELISA, Western blotting and Immunofluorescence assay.RESULTS:Three hybridoma cell lines (5G1, 4F7 and 3H5) stable in secreting specific monoclonal antibodies were successfully obtained. Subclass of IgG belonged to IgG1 (4F7 and 5G1) and IgG2b (3H5), respectively. The ascite titers of these monoclonal antibodies reached 1:10(7). They could specifically bind to recombinant PDCD10 and endogenous and overexpressed PDCD10 proteins proved by ELISA and Western blotting. They failed to react with E.coli lysates and glutathione S-transferase (GST). In addition, these three monoclonal antibodies could recognize different epitopes of PDCD10 proteins assessed by immune fluorescence competitive binding assay. Both endogenous and overexpressed PDCD10 protein mainly located in the nucleus.CONCLUSION:Monoclonal antibodies against PDCD10 with high titers and specificity have been successfully prepared, which has laid the foundation for further study of PDCD10 protein.
Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications

Jingyi Liu,Ximo Xu,Hao Zhong,Mengqin Yu,Naijipu Abuduaini,Sen Zhang,Xiao Yang,Bo Feng

DOI: https://doi.org/10.3390/biomedicines12071446

IF: 4.757

2024-06-28

Biomedicines

Abstract:Immune checkpoint proteins have become recent research hotspots for their vital role in maintaining peripheral immune tolerance and suppressing immune response function in a wide range of tumors. Therefore, investigating the immunomodulatory functions of immune checkpoints and their therapeutic potential for clinical use is of paramount importance. The immune checkpoint blockade (ICB) is an important component of cancer immunotherapy, as it targets inhibitory immune signaling transduction with antagonistic antibodies to restore the host immune response. Anti-programmed cell death-1 (PD-1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies are two main types of widely used ICBs that drastically improve the survival and prognosis of many patients with cancer. Nevertheless, the response rate of most cancer types remains relatively low due to the drug resistance of ICBs, which calls for an in-depth exploration to improve their efficacy. Accumulating evidence suggests that immune checkpoint proteins are glycosylated in forms of N-glycosylation, core fucosylation, or sialylation, which affect multiple biological functions of proteins such as protein biosynthesis, stability, and interaction. In this review, we give a brief introduction to several immune checkpoints and summarize primary molecular mechanisms that modulate protein stability and immunosuppressive function. In addition, newly developed methods targeting glycosylation on immune checkpoints for detection used to stratify patients, as well as small-molecule agents disrupting receptor-ligand interactions to circumvent drug resistance of traditional ICBs, in order to increase the clinical efficacy of immunotherapy strategies of patients with cancer, are also included to provide new insights into scientific research and clinical treatments.
A Peptidic Inhibitor for PD-1 Palmitoylation Targets Its Expression and Functions.

Han Yao,Chushu Li,Fang He,Teng Song,Jean-Philippe Brosseau,Huanbin Wang,Haojie Lu,Caiyun Fang,Hubing Shi,Jiang Lan,Jing-Yuan Fang,Jie Xu

DOI: https://doi.org/10.1039/d0cb00157k

2021-01-01

RSC Chemical Biology

Abstract:Programmed cell death protein 1 (PD-1) is a crucial anticancer target, but the relatively low response rate and acquired resistance to existing antibody drugs highlight an urgent need to develop alternative targeting strategies. Here, we report the palmitoylation of PD-1, discover the main DHHC enzyme for this modification, reveal the mechanism of its effect on PD-1 protein stability, and rationally develop a peptide for targeting PD-1 expression. Palmitoylation promoted the trafficking of PD-1 to the recycling endosome, thus preventing its lysosome-dependent degradation. Palmitoylation of PD-1, but not of PD-L1, promoted mTOR signaling and tumor cell proliferation, and targeting palmitoylation displayed significant anti-tumor effects in a three-dimensional culture system. A peptide was designed to competitively inhibit PD-1 palmitoylation and expression, opening a new route for developing PD-1 inhibitors and combinatorial cancer immunotherapy.
Anti-Tumor Potential of Post-Translational Modifications of PD-1

Xiaoming Xi,Wuli Zhao

DOI: https://doi.org/10.3390/cimb46030136

2024-03-06

Current Issues in Molecular Biology

Abstract:Programmed cell death protein-1 (PD-1) is a vital immune checkpoint molecule. The location, stability, and protein–protein interaction of PD-1 are significantly influenced by post-translational modification (PTM) of proteins. The biological information of PD-1, including its gene and protein structures and the PD-1/PD-L1 signaling pathway, was briefly reviewed in this review. Additionally, recent research on PD-1 post-translational modification, including the study of ubiquitination, glycosylation, phosphorylation, and palmitoylation, was summarized, and research strategies for PD-1 PTM drugs were concluded. At present, only a part of PD-1/PD-L1 treated patients (35–45%) are benefited from immunotherapies, and novel strategies targeting PTM of PD-1/PD-L1 may be important for anti-PD-1/PD-L1 non-responders (poor responders).

biochemistry & molecular biology
Bioengineering and Computational Analysis of Programmed Cell Death Ligand-1 Monoclonal Antibody.

Muhammad Kalim,Hamid Ali,Ashfaq Ur Rehman,Yong Lu,Jinbiao Zhan

DOI: https://doi.org/10.3389/fimmu.2022.1012499

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:The trans-membrane proteins of the B7 family programmed cell death ligand-1 (PD-L1) and programmed death-1 (PD-1) play important roles in inhibiting immune responses and enhancing self-tolerance via T-cell modulation. Several therapeutic antibodies are used to promote T-cell proliferation by preventing interactions between PD-1/PD-L1. Recombinant technology appears to be quite useful in the production of such potent antibodies. In this study, we constructed recombinant molecules by cloning variable regions of the PD-L1 molecule into pMH3 vectors and transferring them into mammalian cell lines for expression. G418 supplementation was used to screen the recombinant clones, which were then maintained on serum-free medium. The full-length antibody was isolated and purified from the medium supernatant at a concentration of 0.5-0.8 mg/ml. Antibody binding affinity was investigated using ELISA and immunofluorescence methods. The protein-protein interactions (PPI) were determined using a docking approach. The SWISS model was utilized for homology modeling, while ZDOCK, Chimera, and PyMOL were used to validate 3D models. The Ramachandran plots were constructed using the SWISS model, which revealed that high-quality structures had a value of more than 90%. Current technologies allow for the accurate determination of antigen-antibody interactions.
High-Resolution Epitope Mapping for Glycosylated Antigens: Pembrolizumab-PD1 as a Case Study

Sara Zhang,Calvin Simmons,Mike Young,Jason Pan

DOI: https://doi.org/10.1101/2024.05.02.592265

2024-05-05

Abstract:High-resolution epitope mapping is important for in-depth activity assessment of antibodies and understanding of their functions, however, glycosylated antigens are challenging for many methods including crystallography. PD1 is a highly glycosylated antigen, and with the traditional HDX-MS method, only 51% sequence coverage could be obtained with multiple epitope residues undetected for Pembrolizumab (Keytruda). By implementing glyco-peptide detection, subzero temperature LC-MS and electron based MSMS fragmentation, the FineMapping methodology enabled 100% sequence coverage and complete epitope characterization for the Pembrolizumab-PD1 system, with amino acid level resolution. As 50% to 70% of proteins in the cell are glycosylated, the middle-down HDX-MS based FineMapping technology presented here should find its wide application on these protein targets. Also, FineMapping detects antibody epitopes directly in solution, without any mutation or modification to either the antigen or the antibody. And its amino acid level resolution combined with its low cost, minimal sample consumption, fast turnaround time, and no need of mutant library or crystallization makes it a competitive methodology for high-resolution epitope mapping.

Biophysics
PD-1 regulation in immune homeostasis and immunotherapy

Minling Gao,Jie Shi,Xiangling Xiao,Yingmeng Yao,Xu Chen,Bin Wang,Jinfang Zhang

DOI: https://doi.org/10.1016/j.canlet.2024.216726

IF: 9.756

2024-02-24

Cancer Letters

Abstract:Harnessing the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis is pivotal in autoimmunity and cancer immunotherapy. PD-1 receptors on immune cells engage with one of its ligands, PD-L1 or PD-L2, expressed on antigen-presenting cells or tumor cells, driving T-cell dysfunction and tumor immune escape. Thus, targeting PD-1/PD-L1 revitalizes cytotoxic T cells for cancer elimination. However, a majority of cancer patients don't respond to PD-1/PD-L1 blockade, and the underlying mechanisms remain partially understood. Recent studies have revealed that PD-1 expression levels or modifications impact the effectiveness of anti -PD-1/PD-L1 treatments. Therefore, understanding the molecular mechanisms governing PD-1 expression and modifications is crucial for innovating therapeutic strategies to enhance the efficacy of PD-1/PD-L1 inhibition. This article presents a comprehensive overview of advancements in PD-1 regulation and highlights their potential in modulating immune homeostasis and cancer immunotherapy, aiming to refine clinical outcomes.

oncology
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

Chu,C.-W.,Caval,T.,Alisson-Silva,F.,Tankasala,A.,Guerrier,C.,Czerwieniec,G.,Läubli,H.,Schwarz,F.

DOI: https://doi.org/10.26508/lsa.202302368

IF: 5.781

2024-01-06

Life Science Alliance

Abstract:Monoclonal antibodies targeting the immune checkpoint PD-1 have provided significant clinical benefit across a number of solid tumors, with differences in efficacy and toxicity profiles possibly related to their intrinsic molecular properties. Here, we report that camrelizumab and cemiplimab engage PD-1 through interactions with its fucosylated glycan. Using a combination of protein and cell glycoengineering, we demonstrate that the two antibodies bind preferentially to PD-1 with core fucose at the asparagine N58 residue. We then provide evidence that the concentration of fucosylated PD-1 in the blood of non–small-cell lung cancer patients varies across different stages of disease. This study illustrates how glycoprofiling of surface receptors and related circulating forms can inform the development of differentiated antibodies that discriminate glycosylation variants and achieve enhanced selectivity, and paves the way toward the implementation of personalized therapeutic approaches.

biology

Prompt effects of high-level irradiation on animal metabolism.

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.

N-glycosylation of PD-1 promotes binding of camrelizumab

Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1

Prognostic Value of Programmed Cell Death Protein 1 Expression on CD8+ T Lymphocytes in Pancreatic Cancer

Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker

Silencing the androgen receptor: new skills for antiandrogen oligonucleotide skin and hair therapy.

Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells

Identification and Functional Characterization of Glycosylation of Recombinant Human Platelet- Derived Growth Factor-Bb in Pichia Pastoris

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Palmitoylation is critically required for cancer intrinsic PD-1 expression and functions

[Preparation and Identification of Monoclonal Antibodies Against Human Programmed Cell Death 10 (PDCD10)].

Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications

A Peptidic Inhibitor for PD-1 Palmitoylation Targets Its Expression and Functions.

Anti-Tumor Potential of Post-Translational Modifications of PD-1

Bioengineering and Computational Analysis of Programmed Cell Death Ligand-1 Monoclonal Antibody.

High-Resolution Epitope Mapping for Glycosylated Antigens: Pembrolizumab-PD1 as a Case Study

PD-1 regulation in immune homeostasis and immunotherapy

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors